GetTopicDetailResponse(id=cef2e9344b2, topicName=缺血/再灌注, introduction=缺血/再灌注, content=null, image=null, comments=2, allHits=1564, url=https://h5.medsci.cn/topic?id=79344, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=73575, tagList=[TagDto(tagId=73575, tagName=缺血/再灌注)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2263659, encodeId=6dd022636596c, content=<a href='/topic/show?id=21d33e36181' target=_blank style='color:#2F92EE;'>#參附注射液#</a>（SF）是由宋代中醫(yī)古籍<a href='/topic/show?id=4ea712664813' target=_blank style='color:#2F92EE;'>#《嚴(yán)氏濟(jì)生方》#</a>中記載的參附湯研制而成的中藥復(fù)方制劑，由<a href='/topic/show?id=8a8624e210a' target=_blank style='color:#2F92EE;'>#人參#</a>和<a href='/topic/show?id=317e10535358' target=_blank style='color:#2F92EE;'>#附子#</a>兩味中藥組成。SF在中醫(yī)中用于治療<a href='/topic/show?id=a1901266498c' target=_blank style='color:#2F92EE;'>#厥證#</a>（與現(xiàn)代休克相對應(yīng)），以其回陽、益氣、救脫的作用而聞名。SF對脊髓、腦、小腸、腎臟和心臟等器官的失血性休克和I/R損傷引起的多器官<a href='/topic/show?id=8c323064e09' target=_blank style='color:#2F92EE;'>#再灌注損傷#</a>具有保護(hù)作用。
肝<a href='/topic/show?id=1063e934733' target=_blank style='color:#2F92EE;'>#缺血再灌注損傷#</a>（HIRI）是外科手術(shù)后不可避免的挑戰(zhàn)。肝臟中<a href='/topic/show?id=b79c6521eb7' target=_blank style='color:#2F92EE;'>#活性氧#</a>（ROS）的積累，沿著<a href='/topic/show?id=cef2e9344b2' target=_blank style='color:#2F92EE;'>#缺血/再灌注#</a>（I/R）引發(fā)的炎癥反應(yīng)，啟動一系列有害的先天免疫反應(yīng)，導(dǎo)致肝細(xì)胞死亡、<a href='/topic/show?id=049b86109ff' target=_blank style='color:#2F92EE;'>#自噬#</a>、循環(huán)障礙、能量代謝失調(diào)和<a href='/topic/show?id=0410639e2b0' target=_blank style='color:#2F92EE;'>#氧化應(yīng)激#</a>。這些反應(yīng)最終導(dǎo)致急性或慢性排斥反應(yīng)，并可能導(dǎo)致<a href='/topic/show?id=fe1b81500a3' target=_blank style='color:#2F92EE;'>#肝衰竭#</a>。, objectTitle=J Ethnopharmacol：參附注射液通過JAK2/STAT3途徑誘導(dǎo)鐵死亡改善肝臟缺血再灌注損傷, objectType=article, longId=874740, objectId=f11e8e474076, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221229/1672303193754_2570354.jpg, objectUrl=/article/show_article.do?id=f11e8e474076, replyNumber=0, likeNumber=45, createdTime=2025-05-06, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=f11e8e474076, moduleTitle=J Ethnopharmacol：參附注射液通過JAK2/STAT3途徑誘導(dǎo)鐵死亡改善肝臟缺血再灌注損傷, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f11e8e474076)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2232019, encodeId=fbee2232019f4, content=<a href='/topic/show?id=b086512e33c' target=_blank style='color:#2F92EE;'>#心肌梗死#</a> <a href='/topic/show?id=cef2e9344b2' target=_blank style='color:#2F92EE;'>#缺血/再灌注#</a>, objectTitle=Cell Prolif 劉洋/劉中民/楊黃恬團(tuán)隊(duì)合作建立模擬心肌缺血/再灌注損傷的人源心臟類器官疾病模型, objectType=article, longId=847734, objectId=c0ba84e7349f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240531/1717122148053_8578774.png, objectUrl=/article/show_article.do?id=c0ba84e7349f, replyNumber=0, likeNumber=68, createdTime=2024-10-20, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c0ba84e7349f, moduleTitle=Cell Prolif 劉洋/劉中民/楊黃恬團(tuán)隊(duì)合作建立模擬心肌缺血/再灌注損傷的人源心臟類器官疾病模型, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c0ba84e7349f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=915925, encodeId=08e591592569, content=細(xì)胞<a href='/topic/show?id=049b86109ff' target=_blank style='color:#2F92EE;'>#自噬#</a>流改善<a href='/topic/show?id=e8fb512451e' target=_blank style='color:#2F92EE;'>#心肌#</a><a href='/topic/show?id=cef2e9344b2' target=_blank style='color:#2F92EE;'>#缺血/再灌注#</a>，這方面仍然能申請基金，相當(dāng)不易。Sirt1/Prx2信號通路，仍然有一定的新意, objectTitle=Sirt1/Prx2通過增強(qiáng)細(xì)胞自噬流改善心肌缺血/再灌注損傷的機(jī)制研究, objectType=nsfc, longId=930374, objectId=676f9303e40f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/sci/nsfc_show.do?id=676f9303e40f, replyNumber=0, likeNumber=286, createdTime=2021-01-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676f9303e40f, moduleTitle=Sirt1/Prx2通過增強(qiáng)細(xì)胞自噬流改善心肌缺血/再灌注損傷的機(jī)制研究, moduleType=nsfc, hrefUrl=http://ermita.cn/sci/nsfc_show.do?id=676f9303e40f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
